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The hematopoietic system undergoes a qualitative change during the embryogenesis of
mostvertebrates. It isdesignatedas theshift ofprimitive todefinitivehematopoiesisand
suitablemicroenvironmentmust be established to support this shift. While studying the
role of platelet derived growth factor receptor a (PDGFR a) in embryonic hematopoiesis,
we found that it was expressed in a stromal cell component of liver, a major site of this
shift, butnot in theyolksac, thesiteofprimitivehematopoiesis.Thus,weconsidered that
development of PDGFRa positive stromal cells is an essential requirement for this shift.
Without PDFGRa positive cell component, erythropoiesis was suppressed in the culture
of fetal liver. Moreover, injection of an antagonistic anti-PDGFRamonoclonal antibody
during embryogenesis suppressed the production of definitive erythrocytes. These
indicated that PDGF exerts its effect on a subset of stromal components to prepare a
microenvironment that can support the definitive erythropoiesis.
Key words: erythropoiesis, erythropoietin, fetal liver, hematopoiesis, PDGF, PDGFRa.
Abbreviations: mAb, monoclonal antibody; PDGFRa, platelet derived growth factor receptor a; CFU, colony
forming unit.
Among about 200 cell types constituting the mammalian
body, hematopoietic cells are generated most rapidly. In
mice, fully mature erythrocytes are detectable at 8 days of
gestation, when most other cell lineages still remain at
intermediate stages. However, this early wave of hemato-
poiesis should undergo a qualitative change to establish
the hematopoietic system that continues throughout life.
This shift of primitive to definitive hematopoiesis is con-
sidered to be a cell autonomous process accompanying
changes in the repertoire of key transcriptional regulator,
such as the c-myb (1) and AML1/RUNX1 (2). However, a
null mutation in erythropoietin (Epo) receptor gene (3, 4)
and Epo gene (3) results in the failure of the production of
adult type mature erythrocytes, indicating that the stro-
mal cell components producing some factors to support
hematopoiesis also play an essential role in the shift
from primitive to definitive erythropoiesis. Although it
has been widely believed that Epo is produced from the
fetal liver and gradually production site of Epo shifts to
the kidney, recent analysis revealed that Epo production is
observed equally in the kidney as well as the fetal liver
during early embryogenesis when fetal hematopoiesis
starts (5). Therefore, erythropoiesis might be affected by
Epo circulating in peripheral blood as well as it produced in
the fetal liver. Most importantly, erythropoiesis cannot be
regulated only by a circulating Epo, but also by matrix
proteins and another cytokine such as c-kit ligand, stem
cell factor (SCF) (6) that are produced from stromal cell
components in hematopoietic tissues.
A recent study of mice bearing a null mutation in platelet
derived growth factor (PDGF)-B (7) or its receptor
(PDGFR)b (8) showed that most mutant embryos develop
fatal hemorrhage before birth and this hemorrhage leads
to erythroblastosis, macrocytic anemia and thrombocyte-
penia. Then anemia looked in those mutants was indicated
as the secondary effect of hemorrhage. It was shown, how-
ever, anemia occurs in mutants before any obvious sign of
bleeding. Then PDGF-B and PDGFRb may be involved in
the production of erythrocyte. Consistent with these func-
tional studies, several investigators have detected
PDGFRa in embryonic erythroblasts by in situ hybridiza-
tion (9) or immunohistochemistry (10). Moreover, since
c-Kit that belongs to the same family of receptor tyrosine
kinases, are involved in the proliferation of hematopoietic
stem cells (11), and differentiation of erythroblast (6).
PDGFRa, when expressed in the hematopoietic stem
cell, should be able to take over the same function.
Although mice carrying a targeted null mutation of
PDGFRa gene were reported to show early embryonic leth-
ality, hematological analysis has not been performed (12).
Previously, we established a monoclonal antibody (mAb)
that recognizes the ligand-binding domain of murine
PDGFRa. Hence, all functional PDGFRa should be recog-
nized by this mAb (13–15). We then re-evaluated the role of
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PDGF signal in the embryonic hematopoiesis. In this
study, we examined which cells in the hematopoietic tis-
sues express PDGFRa, and how they are involved in hema-
topoiesis. We showed that PDGFRa is not expressed in
hematopoietic cells, whereas it is in the stromal/fibroblas-
tic cells of embryonic hematopoietic tissues, and that
PDGFRa plays a role for the shift from primitive to defi-
nitive erythropoiesis. This indicates that the generation
and stimulation of PDGFRa+ stromal cell component
play an essential role in establishing the microenviron-
ment that supports the shift of erythropoiesis from primi-
tive to the adult type.
MATERIALS AND METHODS
Animals—C57BL/6 mice and pregnant mice were pur-
chased from Japan SLC Inc. (Shizuoka, Japan). The noon
when a vaginal plug was detected was designated as
embryonic day 0.5 of gestation (E0.5).
Immunohistochemistry—Tissue fixation procedures
were basically as described (16). Fixed specimens were
embedded in polyester wax and sectioned at 8 mm as
described (17). Immunostaining proceeded as described
(15). In brief, sections were incubated with anti–c-Kit mAb,
ACK2 (18, 19), anti-PDGFRa mAb, APA5 (13–15), anti-flk1
mAb, AVAS12 (20), or anti-embryonic (21) or -adult (Cappel,
Durham, NC) hemoglobin polyclonal antibody. Sections
were incubated with a peroxidase conjugated secondary
antibody, anti–rat-IgG antibody (Biosource, Camarillo,
CA) for ACK2, APA5 and AVAS12, or anti–rabbit-IgG (Bio-
source) for both of anti-hemoglobin antibody and then color
reaction was performed with diaminobenzidine (Dojin
Chem., Kumamoto, Japan).
Procedure of whole-mount immunohistostaining was the
same as described (15). In brief, the primary antibody was
visualized by incubating 1 mg/ml peroxidase-conjugated
anti–rat-Ig antibody (Biosource) overnight at 4C. After
extensive washing, the specimens were soaked in PBS con-
taining 0.1% Triton X-100, 0.05% NiCl2 and 250 mg/ml
diaminobenzidine (Dojin Chem.) for 10–30 minutes, then
hydrogen peroxide was added to a final concentration of
0.01%. The enzymatic reaction proceeded until the desired
color-intensity was reached, then the specimens were
rinsed 3–4 times in PBST.
Cell Preparation and Flow Cytometry—The fetal liver
at E12.5 was dissociated by Dispase II (Boehringer
Mannheim, Mannheim, Germany) and drawn through a
23G needle. Fetal liver cells (5· 105) prepared from embryos
(16) were suspended in 50 ml of 5% FCS containing PBS. The
cell-staining procedure for the flow cytometry was
as described previously (17). The monoclonal antibodies
(mAbs) used in immunofluorescence staining were anti–
b1 integrin antibody, anti-lineage (ter119, Gr-1, Mac-1,
B220, CD4, CD8) antibodies (all purchased from Pharmin-
gen), anti-PDGFRa antibody (APA5) and anti–c-Kit anti-
body (ACK2). All mAbs were purified and conjugated with
either FITC, PE (phycoerythrin), or biotin. Biotinylated
antibodies were visualized with PE-conjugated streptavi-
din or APC-conjugated streptavidin (Pharmingen). Cells
were incubated for 5 min on ice with 1:100 dilution of
CD16/32 (FcgIII/II Receptor, (1:100) [FcblockTM]; Phar-
mingen) prior to staining with primary antibody. The
stained cells were analyzed by FACS calibur (Becton
Dickinson, San Jose, CA) and sorted by EPICS Flow
cytometer (ALTRA: Beckman Coulter, San Jose, CA).
Sorted TER119 positive erythroid cells from APA5 or con-
trol antibody injected fetal liver were attached on glass
and stained with anti–embryonic hemoglobin antibody as
described previously (17).
Cell Culture and CFU-c Analysis—Single cell suspension
from E12.5 fetal liver was stained with anti-PDGFRa anti-
body, and then PDGFRa positive fraction was eliminated
by cell sorting. 1 · 105 sorted fetal liver cells not containing
PDGFRa positive cells and fetal liver cells containing both
PDGFRa negative and positive cells once sorted for making
even condition in cell preparation were cultured on 12 well
fibronectin coated dishes (Becton Dickinson, Bedford, MA)
in RPMI (Sigma, St. Louis, MO) containing 10% FCS in the
presence or absence of 10 ng/ml PDGF (Peprotech, London,
UK) at 37C in a 5% CO2 incubator for 7 days. For the
analysis of Epo induction from fetal liver cells, fetal liver
cells were harvested after 24 h and RNA was extracted.
After culturing, all cells were harvested and subjected to
the colony formation unit in culture (CFU-c) assay as
described previously (22). Colony containing only erythro-
cyte was counted as CFU-E after 4 days of culturing. The
total number of hematopoietic colonies [i.e., CFU-
granulocyte (G), macrophage (M) and granulocyte/macro-
phage (GM)] was counted as another CFU-c after 7 days of
culturing.
RT-PCR Analysis—The RNeasy Mini kit (Qiagen
GmbH, Hilden, Germany) was used for isolation of total
RNA from cells from fetal liver. Total RNA was reverse
transcribed using the RT for PCR kit (Clontech, Palo
Alto, CA). The cDNA was amplified using Advantage Poly-
merase Mix (Clontech) in a GeneAmp PCR system model
9700 (Perkin-Elmer Inc., Norwalk, CT) by 30 to 35 cycles.
The sequences of the gene-specific primers for RT-PCR
were as follows: 50-EPO (TAGAAGTTTGGCAAGGCCTG),
30-EPO (CGTGTACAGCTTCAGTTTCC), 50-TPO (CCTCT-
TCTTGAGCTTGCAAC), 30-TPO (AGCCCATGAGTTCCA-
TTCAC), 50-SCF (TAACCCTCAACTATGTCGCC), 30-SCF
(TCACTAGTGTCAGATGCCAC), 50-b-actin (CCTAAGGC-
CAACCGTGAAAAG), 30-b-actin (TCTTCATGGTGCTAG-
GAGCCA). Each cycle consisted of denaturation at 94C
for 30 s, and annealing/extension at 70C for 4 min.
Maternal Injection of Monoclonal Antibodies—Pregnant
mice were given an intravenous injection of anti-PDGFRa
mAb, APA5 (2 mg) daily from E9.5 to E13.5. Rat anti–
murine IL-7 receptor mAb, A7R34 (23) was used as an
isotype-matched control and injected as described above.
The mice injected with antibodies were sacrificed at E15.5
by cervical dislocation and embryos were fixed with cold 4%
paraformaldehyde containing PBS (pH 7.4). Fixed speci-
mens were embedded into polyester wax and sectioned at
5 mm.
RESULTS
Expression of PDGFRa in Fetal Hematopoietic Tissues—
To gain insight on the expression of PDGFRa in the
fetal tissues, embryos were whole mount immunohistos-
tained by the anti-PDGFRa mAb, APA5, with particular
focus in the yolk sac where hematopoiesis has been demon-
strated to take place. Because previous studies (24–27)
suggest that c-Kit is expressed and functioning in the
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fetal hematopoietic stem cells, embryos were also stained
with the anti–c-Kit mAb, ACK2.
Although it was suggested that hematopoietic cells in the
blood island express PDGFRa, we could not detect
PDGFRa expression in any cells in the yolk sac (Fig. 1A)
in embryonic day (E) 9.5. In contrast, blood islands in the
yolk sac were stained as scattered dots by c-Kit+ cells (Fig.
1B). In this stage, yolk sac was organized by the nest of
Flk-1 positive endothelial cells (Fig. 1C).
To further analyze the cells expressing PDGFRa in the
hematopoietic organ, we immunostained the sections of
E12.5 liver. PDGFRa staining was most intense in the
mesenchymal cells surrounding the fetal liver. In addition,
we also detected PDGFRa+ cells scattered in the parench-
yma of developing fetal liver (Fig. 1D). These are bipolar
fibroblastic cells and different from the round cells stained
by anti–c-Kit mAb, ACK2 (Fig. 1E). Moreover, PDGFRa-
staining remarkably differed from that by anti-Flk1 mAb
that marks vascular endothelium (Fig. 1F).
To confirm that no hematopoietic cell lineages in the
embryonic tissues express PDGFRa, we performed flow-
cytometric analysis of fetal liver cells from E12.5 embryos
using a number of hematopoietic cell markers. As shown
in Fig. 2, PDGFRa cells are very few among whole fetal
liver cells (0.4%) as observed in immunohistostaining of
fetal liver section and PDGFRa cells were undetectable
in TER119+ erythroblasts, which supposedly express
PDGFRa. Moreover, there was no PDGFRa+ cell among
the hematopoietic lineage cells expressing CD4, CD8,
B220, Mac-1 Gr-1. In the hematopoietic stem cells desig-
nated as Lin (mixture of B220, Mac-1, TER119, CD4, 8, and
Gr-1) negative and c-Kit positive fraction, we could not
Fig. 1. PDGFRa expression in
the fetal liver. Whole-mount
staining in yolk sac of E9.5 embryos
(A–C) with mAbs, (A) anti-PDGFRa
antibody, (B) anti–c-Kit antibody,
and (C) anti–Flk-1 antibody. In
the yolk sac, PDGFRa expression
is not found (A), whereas c-Kit
expressing spots are scattered
throughout yolk sac (B) and Flk-1
positive cells form vascular nests
(C). Immunohistochemical stain-
ing of sections from E12.5 fetal
liver. (D) PDGFRa, (E) c-Kit and
(F) Flk-1 expression. Arrows in
(D) indicate PDGFRa positive cells
in parenchyma of fetal liver. Bar
indicates 25 mm.
Fig. 2. Flow cytometric analysis
of the fetal liver. Fetal liver cells
from E12.5 embryo were stained
with anti-PDGFRa and TER119,
mixture of anti-CD4 and anti-CD8
mAbs, B220, mixture of Mac-1 and
Gr-1, anti–c-Kit mAb, or anti-b1
integrin mAb. Mixture of anti–
Mac-1, -B220, -TER119, -CD4, -CD8
and Gr.1 mAbs was used as lineage
markers. The vertical and horizon-
tal lines indicate the threshold of
fluorescence intensity of negative
control staining. The percentage of
cells in each quadrant is shown in
the top right-hand corner of each
panel.
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observe the expression PDGFRa, whereas almost all
PDGFRa cells express b1 integrin, one of the mesenchymal
marker. Moreover, we could not detect PDGFRa cells of
hematopoietic lineage in the yolk sac (data not shown).
These results indicated that PDGFRa is not expressed in
any embryonic hematopoietic lineage cells, whereas it was
expressed in the stromal cell component.
Anti-PDGFRa Antibody Suppressed the Production of
Adult type Erythrocytes in Embryos—To investigate the
role of PDGFRa in hematopoiesis, we used anti-PDGFRa
antibody that blocks the binding of PDGFRa to both
PDGF-A and PDGF-B (13, 14) and observed fetal liver
hematopoiesis. Pregnant mice were given an intravenous
injection of 2 mg anti-PDGFRa antibody every day from
E9.5 to E13.5, and the embryos were examined on E15.5.
As shown in Fig. 3, the numbers of mature enucleated
erythrocytes in the fetal liver treated with anti-PDGFRa
antibody (Fig. 3B) were small compared with those treated
with control Ig, anti–IL7 receptor (R) mAb (Fig. 3A) and
there were many nucleated erythrocytes (arrow heads) in
anti-PDGFRa antibody treated fetal liver (Fig. 3B). When
hemoglobin staining was performed, many erythrocytes in
the fetal liver treated with anti-PDGFRa antibody were of
the fetal type stained with anti–embryonic and anti–adult
type hemoglobin antibody (Fig. 3, D and F). We sorted
TER119 positive erythroid cells from the fetal liver and
counted the number of embryonic hemoglobin positive
fetal type erythroid cells among total erythroid cells.
Result revealed that 37 – 7% (n = 5) among total
TER119 positive erythroid cells was of fetal type. On the
other hand, most erythrocytes in the embryo that had been
given control anti-IL7R mAb expressed adult type hemo-
globin but not fetal hemoglobin (Fig. 3, C and E). As
described above, we observed the ratio of fetal type ery-
throid cells among total TER119 positive erythroid cells
obtained by cell sorting. Result revealed that 5 – 1%
(n = 5) was of fetal type. No substantial defect was detected
in cells of other lineages confirmed by May-Gruenwald-
Giemsa staining and flow cytometric analysis (data not
shown).
This result suggested that the PDGFRa signal is
involved in the generation of adult type erythrocytes.
PDFGRa Positive Cells Are the Source of Erythropoietin
in the Fetal Liver and Support Definitive Erythropoiesis—
Epo and Epo receptor–deficient mice die in utero due to a
marked reduction in the number of committed fetal liver
derived erythroid progenitors, resulted in lack of enu-
cleated mature erythrocyte development (3, 4). The fetal
liver acts as the primary site of synthesis of Epo (5, 28).
Therefore, we observed the expression of Epo in PDFGRa
positive cells from the fetal liver. As shown in Fig. 4, Epo
expression was observed in PDGFRa positive cells but not
in PDGFRa negative cells in the fetal liver. On the other
hand, in case of expression of other growth factors such as
thrombopoietin (TPO) and stem cell factor (SCF), which
are involved in generation of hematopoietic progenitors,
PDGFRa negative fraction expressed both of TPO and
SCF but PDGFRa positive fraction did not express SCF.
These indicated that PDGFRa positive cells in the fetal
Fig. 4. Expression of erythropoietin in PDGFRa positive
cells in the fetal liver. Expression of erythropoietin (EPO),
thrombopoietin (TPO), and stem cells factor (SCF) was examined
by RT-PCR analysis in (1) PDGFRa negative fraction, (2) PDGFRa
positive fraction, and (3) whole cells from E12.5 fetal liver.
(4) Distilled water. b-actin was used for internal control.
Fig. 3. Injection of anti-PDGFRa
antibody suppressed the shift
from the primitive to definitive
erythropoiesis. (A, C, E) anti–IL-
7R mAb, A7R34 (2 mg) as an isotype
matched control or (B, D, F) Anti-
PDGFRa mAb, APA5 (2 mg) was
injected intravenously into preg-
nant mice every day from E9.5 to
E13.5, and embryos were dissected
at E15.5. The sections of the livers
were either hematoxylin-eosin
stained (A, B) or immunohistos-
tained with anti-embryonic hemo-
globin (C, D) or anti-adult
hemoglobin (E, F). Arrow heads
in (A) and (B) indicate nucleated
erythrocytes. Insets in (A) and (B)
are high power views indicated by
box, respectively. Insets in (A) and
(B) show enucleated erythrocytes
and nucleated erythrocytes, respec-
tively. Bar indicates 25 mm.
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liver can support definitive erythropoiesis by producing
Epo, and that blockade of PDGFRa signaling by anti-
PDGFRa antibody injection affected the generation of
enucleated mature erythrocyte. However, it is unclear
whether total administration of PDGFRa antibody directly
affects the PDGFRa positive cells in the fetal liver or not
and PDGFRa signaling in the fetal liver is actually
involved in erythropoiesis. To overcome these issues, we
cultured fetal liver cells in the presence or absence of
PDGFRa positive cells or PDGF-AA and observed the
development of erythrocyte progenitors by the analysis
of colony forming unit (CFU)–erythrocyte (E) formation
(Fig. 5A).
Results showed that the number of CFU-containing
granulocytes (G), macrophage (M), granulocyte/macro-
phage (GM) slightly increased by the addition of PDGF-AA
in the presence of PDGFRa positive cells. Moreover, deple-
tion of PDGFRa positive cells from total fetal liver cells
slightly reduced the generation of CFU-G, M, and GM
formation. However, in both cases, there are no significant
differences statistically (Fig. 5B). On the other hand, in
case of CFU-E formation (Fig. 5C), the number of
CFU-E increased by the addition of PDGF-AA in the pre-
sence of PDGFRa positive cells. Moreover, depletion of
PDGFRa positive cells from total fetal liver cells dramati-
cally reduced the generation of CFU-E.
Finally, we observed whether or not PDGF-AA or -BB
affect the Epo expression in the culture of fetal liver cells.
As shown in Fig. 6, both of PDGF-AA and PDGF-BB
induced the Epo expression in fetal liver cells.
Taken together, these indicated that PDGFR signal via
PDGFRa positive cells are required for the generation of
definitive erythrocytes in the fetal liver.
DISCUSSION
The question addressed in this study was how PDGF is
involved in the embryonic erythropoiesis. Studies of mice
bearing a null mutation of PDGF-B (7) and its receptor (8)
indicated that these signals might be involved in the fetal
erythropoiesis, as anemia is a key phenotype of these
mutant embryos. In this study, we demonstrated that
PDGFRa positive cells in the fetal liver regulate definitive
erythropoiesis. Adult type erythrocyte precursors may
express PDGFRa that functions in their proliferation.
Although several studies support this notion (9, 29), the
results presented here argue against the expression of
PDGFRa in hematopoietic cells at any stage of embryogen-
esis. We showed this by immunohistostaining and by flow-
cytometry. It is difficult to explain the discrepancy between
our results and those of others. As our mAb recognizes the
Fig. 5. PDGFRa positive cells in
the fetal liver can support ery-
thropoiesis. (A) FACS analysis of
PDGFRa positive cells existing in
the mouse fetal liver at E12.5 and
schematic presentation of the step
wise culture system with fetal liver
cells of E12.5 mouse embryos. Total
fetal liver cells (total fetal liver) or
PDGFRa negative fetal liver cells
(total liver – PDGFRa+ cells) were
cultured for 7 days in the presence
or absence of PDGF-AA and trans-
ferred to semi-solid culture condi-
tion. The number of CFU-E or
another CFU-c (CFU-G, GM, and
M) was counted on day 4 or day 7,
respectively. (B) Comparison of the
total number of CFU-G, GM, and
M derived from culture of fetal
liver cells as above in the presence
or absence of PDGFRa positive
cells or PDGF-AA. (C) Comparison
of the total number of CFU-E
derived from culture of fetal liver
cells as above in the presence or
absence of PDGFRa positive cells
or PDGF-AA.
Fig. 6. Expression of erythropoietin in fetal liver cells sti-
mulated by PDGF. Expression of erythropoietin (EPO) was
examined by RT-PCR analysis in cultured fetal liver cells in the
absence of PDGF (1), in the presence of 10 ng/ml PDGF-AA (2), in
the presence of 10 ng/ml PDGF-BB. (4) Distilled water. b-actin was
used for internal control.
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ligand-binding site of PDGFRa, functional PDGFRa mole-
cules should be recognized by our mAb. Thus, the positive
signal found in embryonic erythrocytes by other groups
may be due to either the nonfunctional, truncated mole-
cule, or non-specific background. Indeed, fetal erythrocytes
display higher background upon in situ hybridization.
We then examined which cells express PDGFRa and how
PDGFRa positive cells are involved in hematopoiesis. The
present results suggested that stromal cells rather than
erythrocyte progenitors express PDGFRa. Using a mAb
specific to Flk1 that is expressed in the vascular endothe-
lium, we demonstrated that PDGFRa+ cells are different
from the vascular endothelium. Thus, the effect of PDGF
on erythropoietic progenitors should be transferred indir-
ectly to the erythrocyte progenitors via PDGFRa+ stromal
cells in the microenvironment. However, an anti-PDGFRa
antibody injection into adult mice did not suppress the
adult erythropoiesis (data not shown). This suggested
that the PDGF signal plays an essential role in establish-
ing the microenvironment to initiate adult type erythro-
poiesis, whereas the established adult intramarrow
microenvironment is maintained by different mechanisms.
A phenotype found in the anti-PDGFRa antibody
injected mouse was similar with mice that bear a null
mutation either of erythropoietin (3) or erythropoietin
receptors (3, 4), as maturation arrest of definitive erythroid
progenitor cells and complete lack of mature enucleated
erythrocyte are key phenotypes. Though anti-PDGFRa
antibody injected mouse had a few enucleated mature
erythrocytes, primitive erythrocytes were abundantly
observed in E15.5 fetal liver of anti-PDGFRa antibody
injected embryo. Moreover, the production of erythropoie-
tin starts in fetal liver at around E13 earlier than in the
kidney (30, 31). This suggests the possibility that PDGFRa
provides an important signal for establishing the stromal
component that can secrete Epo.
In this context, it is notable that PDGFRa expression in
the stromal cell component is found in the fetal liver, but
not in the yolk sac. Hence, the first wave of erythropoiesis
is independent from the PDGFRa signal and therefore all
the erythrocytes produced from yolk sac remain primitive.
However, as soon as active hematopoiesis shifts to the fetal
liver where the microenvironment is stimulated by PDGF,
the shift to adult type erythropoiesis would be facilitated.
In this respect, stromal cells in the hematopoietic site can
provide a molecular cue to shift to the adult type erythro-
cytes. In deed, we found that Epo expression is observed in
PDGFRa positive cell component but not in PDGFRa nega-
tive cell component of E12.5 fetal liver and we found that
Epo expression is induced by PDGF-AA or PDGF-BB
directly in in vitro culture of fetal liver cells. If the induc-
tion of Epo at the site of hematopoiesis is a role of PDGFRa,
then the anti-PDGFRa antibody injection would not sup-
press adult erythropoiesis because the site of Epo produc-
tion shifts to the kidney in adult (32).
It has been reported that Epo mRNA in the liver is
expressed in the fibroblast-like Ito cells and it in the kidney
is expressed in proximal tubular cells (5). We tried to isolate
PDGFRa positive cells from the fetal liver and to culture
those cells. However, we could not succeed to culture and
maintain the survival of PDGFRa positive cells by means of
generally used in vitro culture system. An attempt to isolate
PDGFRa+ stromal cell components is currently underway in
our laboratory to understand the characteristic differences
between PDGFRa+ cells in the fetal liver and proximal tub-
ular cells in the kidney for the regulation of Epo production.
Whether suppression of PDGFRa signal decreases the
expression of Epo or affects the CFU-E formation or not is
under way using the isolated PDGFRa+ cells from fetal
liver or such isolated PDGFRa+ cells with hematopoietic
progenitors from fetal liver.
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